Home / Market News / $ABT
fiscal.ai Corporate Catalyst Impact 75/100 ● positive

Abbott Announces Positive 30-Day Results from TECTONIC Clinical Trial for SonicForce™ Coronary IVL System

Nov 2, 2026, 2:03 AM UTC · Primary ticker $ABT

Abbott announced positive 30-day results from its TECTONIC clinical trial for the SonicForce™ Coronary IVL System, meeting primary safety and effectiveness endpoints. This indicates a strong potential for a new medical device to address severe coronary artery calcification, which could boost Abbott's medical device segment.

Abbott announced that its TECTONIC clinical trial for the SonicForce™ Coronary IVL System met its primary safety and effectiveness endpoints, with a very low 0.3% target lesion failure rate. This is significant because it validates the efficacy and safety of a new device designed to treat severe coronary artery calcification, a complex condition. This positive outcome positions Abbott for potential regulatory approval and market entry for SonicForce, strengthening its cardiovascular device portfolio. For traders, this represents a short-term positive catalyst for ABT, as it de-risks a key product in development and signals future revenue growth in a specialized medical device market. The long-term implication is increased market share and competitive advantage in interventional cardiology, potentially putting pressure on competitors like Boston Scientific and Medtronic.

$ABT positive Successful clinical trial for new medical device
$BSX neutral Competitor in cardiovascular devices
$MDT neutral Competitor in cardiovascular devices
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.